Brian Y Park1, Rachel N Grisham2, Bjørnar den Hollander3, Dharmarao Thapi2, Tara Berman2, Elisa de Stanchina4, Qin Zhou5, Gopa Iyer6, Carol Aghajanian2, David R Spriggs2. 1. a Department of Internal Medicine , Loma Linda University Medical Center , Loma Linda , California , USA. 2. b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA. 3. c Department of Pharmacology , Faculty of Medicine, University of Helsinki , Helsinki , Finland. 4. d Antitumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center , New York , New York , USA. 5. e Department of Epidemiology and Statistics , Memorial Sloan-Kettering Cancer Center , New York , New York , USA. 6. f Department of Medicine , GU Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Abstract
OBJECTIVES: To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer. METHODS: Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56. RESULTS: Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups. CONCLUSIONS: We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.
OBJECTIVES: To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer. METHODS:Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56. RESULTS:Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups. CONCLUSIONS: We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.
Authors: Francesco Caiazza; Alyson Murray; Stephen F Madden; Naoise C Synnott; Elizabeth J Ryan; Norma O'Donovan; John Crown; Michael J Duffy Journal: Endocr Relat Cancer Date: 2016-03-01 Impact factor: 5.678
Authors: Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Dawn R Cochrane; Sebastián Bernales; Britta M Jacobsen; Diana M Cittelly; Erin N Howe; Nicholas C D'Amato; Nicole S Spoelstra; Susan M Edgerton; Annie Jean; Javier Guerrero; Francisco Gómez; Satyanarayana Medicherla; Iván E Alfaro; Emma McCullagh; Paul Jedlicka; Kathleen C Torkko; Ann D Thor; Anthony D Elias; Andrew A Protter; Jennifer K Richer Journal: Breast Cancer Res Date: 2014-01-22 Impact factor: 6.466
Authors: Beryl L Manning-Geist; Sushmita B Gordhandas; Dilip D Giri; Alexia Iasonos; Qin Zhou; Jeffrey Girshman; Roisin E O'Cearbhaill; Dmitriy Zamarin; Stuart M Lichtman; Paul J Sabbatini; William P Tew; Karen Li; Autumn S McDonnell; Emeline M Aviki; Dennis S Chi; Carol A Aghajanian; Rachel N Grisham Journal: Gynecol Oncol Date: 2021-11-08 Impact factor: 5.304
Authors: Suriyan Ponnusamy; Sarah Asemota; Lee S Schwartzberg; Fouzia Guestini; Keely M McNamara; Mariaelena Pierobon; Alba Font-Tello; Xintao Qiu; Yingtian Xie; Prakash K Rao; Thirumagal Thiyagarajan; Brandy Grimes; Daniel L Johnson; Martin D Fleming; Frances E Pritchard; Michael P Berry; Roy Oswaks; Richard E Fine; Myles Brown; Hironobu Sasano; Emanuel F Petricoin; Henry W Long; Ramesh Narayanan Journal: iScience Date: 2019-10-23
Authors: Susana Banerjee; Holly Tovey; Rebecca Bowen; Elizabeth Folkerd; Lucy Kilburn; Jennifer McLachlan; Marcia Hall; Nina Tunariu; Ayoma Attygalle; Joao Paulo Da Silveira Nogueira Lima; Sophie Perry; Peter Chatfield; Margaret Hills; Stan Kaye; Gert Attard; Mitch Dowsett; Judith M Bliss Journal: Ther Adv Med Oncol Date: 2020-12-29 Impact factor: 8.168
Authors: Jose A Colina; Katherine E Zink; Kanella Eliadis; Reza Salehi; Emma S Gargus; Sarah R Wagner; Kristine J Moss; Seth Baligod; Kailiang Li; Brenna J Kirkpatrick; Teresa K Woodruff; Benjamin K Tsang; Laura M Sanchez; Joanna E Burdette Journal: Cancers (Basel) Date: 2021-04-16 Impact factor: 6.639